MACK

Merrimack Pharmaceuticals Inc.

Price

return (12m)

0.00%

p/e

1.06

p/bv

0.96

DIVIDEND YIELD

0.00%

MACK price

Merrimack Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment MACK

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals MACK

Valuation

P/E

1.06

Sector -5.81

Industry -5.81

P/BV

0.96

Sector 1.45

Industry 1.45

P/Revenue (PSR)

Sector -5.82

Industry -5.82

EV/EBITDA

-316.15

Sector -58,996,766.14

Industry -58,996,766.14

EV/EBIT

-316.15

Sector -34,683,138.95

Industry -34,683,138.95

P/EBITDA

-136.57

Sector -6.08

Industry -6.08

P/EBIT

-138.90

Sector -6.03

Industry -6.03

P/Total Assets

0.87

Sector 1.24

Industry 1.24

P/Net Current Assets

0.96

Sector -10,172,795.43

Industry -10,172,795.43

P/Working Capital

0.96

Sector -12,104,673.65

Industry -12,104,673.65

EPS

14.32

Sector -3.12

Industry -3.12

BVPS

15.83

Sector 1.33

Industry 1.33

Efficiency

Gross Margin

0.00%

Sector 30.38%

Industry 30.38%

EBITDA Margin

Sector -16,743.16%

Industry -16,743.16%

EBIT Margin

Sector -4,275,111.13%

Industry -4,275,111.13%

Operating Margin

0.00%

Sector -47.21%

Industry -47.21%

Net Profit Margins

0.00%

Sector -47.95%

Industry -47.95%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

90.44%

Sector -102.69%

Industry -102.69%

ROA

82.05%

Sector -91.11%

Industry -91.11%

ROIC

-1,375.84%

Sector -1,699.17%

Industry -1,699.17%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

10.78

Sector 2.91

Industry 2.91

Net Debt / EBITDA

0.00

Sector -14.61

Industry -14.61

Net Debt / EBIT

0.00

Sector -7.15

Industry -7.15

Net Debt / Equity

0.00

Sector -33,112.88

Industry -33,112.88

Gross Debt / Equity

0.00

Sector -0.48

Industry -0.48

Equity/Assets

0.91

Sector 0.29

Industry 0.29

Liabilities/Assets

0.91

Sector 0.35

Industry 0.35

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Merrimack Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$0.00

Fair Value

$71.42

Upside Return potential.

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals MACK

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
MACK	1.06	0.96	90.44%	0.00%	$211.82 M	0.00%
JNJ	29.40	7.28	24.76%	2.04%	$618.44 B	21.48%
PFE	18.75	1.55	8.29%	6.97%	$140.44 B	11.83%
ABBV	71.07	0.00	-%	2.66%	$448.43 B	9.80%
NVO	11.00	6.65	60.40%	3.96%	$208.75 B	37.15%
MRK	35.97	7.00	19.45%	2.58%	$321.35 B	13.59%
AZN	25.16	5.22	20.74%	1.89%	$262.79 B	17.02%
GILD	17.55	6.90	39.33%	2.47%	$161.73 B	30.99%
BMY	14.12	5.87	41.59%	3.91%	$131.06 B	18.87%
ZTS	12.23	10.00	81.75%	2.69%	$32.33 B	27.79%
REGN	17.58	2.40	13.65%	0.49%	$76.11 B	27.86%
HALO	27.82	44.19	158.82%	0.00%	$9.70 B	23.13%
AMGN	26.41	22.42	84.87%	2.57%	$206.02 B	20.96%
MCK	22.00	-125.59	-570.98%	0.38%	$104.74 B	1.18%
VRTX	27.75	6.22	22.41%	0.00%	$120.39 B	35.51%
CAH	34.61	-20.14	-58.20%	0.89%	$53.82 B	0.62%
HRMY	13.88	2.22	16.00%	0.00%	$2.02 B	16.20%
BIIB	36.30	1.61	4.43%	0.00%	$30.30 B	8.32%
MEDP	32.46	36.77	113.29%	0.00%	$15.95 B	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

MACK Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	12/12/2019	12/23/2019	0.50070000
Dividends	08/26/2019	09/05/2019	1.49670000
Dividends	05/15/2017	05/26/2017	10.55000000

ABOUT Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

United States

33 years

Founded: 1993

2012

Time since IPO - 14 years

294

Employees

Merrimack Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $211.82 million, with shareholders equity totaling $221.65 million.

The company employs approximately 294 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Merrimack Pharmaceuticals Inc. reported $- in revenue, generating net income of $200.46 million.

Key financial metrics include a P/E ratio of 1.06, a price-to-book (P/B) ratio of 0.96, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker MACK.

Market cap

$211.82 million

Net worth

$221.65 million

$221,650,000.00

Assets

$244.32 million

$244,320,000.00

Total Shares Outstanding

14.00 million

14,000,000

Average Daily Trading Volume

$230.73 Thousand

$230,726.92

Sector

Health Care

Industry

Biotechnology

MACK

MACK revenue and profits

Financial Results MACK

DRAG THE FRAME TO SEE MORE DATA

MACK cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$859.49 23,49% (12M)

P/E

22.00

0.38%

ROE

-570.98%

P/BV

-125.59

CAH - Cardinal Health

$229.02 48,35% (12M)

P/E

34.61

0.89%

ROE

-58.20%

P/BV

-20.14

JNJ - Johnson & Johnson

$258.25 58,21% (12M)

P/E

29.40

2.04%

ROE

24.76%

P/BV

7.28

ABBV - AbbVie

$253.35 35,07% (12M)

P/E

71.07

2.66%

ROE

P/BV

0.00

MRK - Merck & Co.

$130.85 70,49% (12M)

P/E

35.97

2.58%

ROE

19.45%

P/BV

7.00

AZN - AstraZeneca

$170.49 16,29% (12M)

P/E

25.16

1.89%

ROE

20.74%

P/BV

5.22

NVO - Novo Nordisk

$46.99 0,92% (12M)

P/E

11.00

3.96%

ROE

60.40%

P/BV

6.65

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$859.49 23,49% (12 M)

P/L

22.00

0.38%

ROE

-570.98%

P/VP

-125.59

CAH - Cardinal Health

$229.02 48,35% (12 M)

P/L

34.61

0.89%

ROE

-58.20%

P/VP

-20.14

JNJ - Johnson & Johnson

$258.25 58,21% (12 M)

P/L

29.40

2.04%

ROE

24.76%

P/VP

7.28

ABBV - AbbVie

$253.35 35,07% (12 M)

P/L

71.07

2.66%

ROE

P/VP

0.00

MRK - Merck & Co.

$130.85 70,49% (12 M)

P/L

35.97

2.58%

ROE

19.45%

P/VP

7.00

AZN - AstraZeneca

$170.49 16,29% (12 M)

P/L

25.16

1.89%

ROE

20.74%

P/VP

5.22

NVO - Novo Nordisk

$46.99 0,92% (12 M)

P/L

11.00

3.96%

ROE

60.40%

P/VP

6.65

Frequently Asked Questions

What is the price of Merrimack Pharmaceuticals (MACK) today?

A cotação de Merrimack Pharmaceuticals (MACK) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Merrimack Pharmaceuticals (MACK) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Merrimack Pharmaceuticals (MACK) e dados de ações do Ibovespa e mercados internacionais.

Quando Merrimack Pharmaceuticals (MACK) paga dividendos?

Merrimack Pharmaceuticals (MACK) não distribuiu dividendos no último ano.

Is Merrimack Pharmaceuticals (MACK) a good investment?

Atualmente, Merrimack Pharmaceuticals (MACK) está cotada a US$ 0.00, com um P/L de 1.06, representando um desvio de -7,980% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Merrimack Pharmaceuticals (MACK) stock?

Investir em ações de Merrimack Pharmaceuticals (MACK) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Merrimack Pharmaceuticals (MACK) yield today?

A rentabilidade de Merrimack Pharmaceuticals (MACK) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Merrimack Pharmaceuticals (MACK) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

MACK

Merrimack Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment MACK

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

current DY: 0.00%

5-year average DY: 0.00%

type

Ex - Dividend Date

payment date

value

ABOUT Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Inc.

United States

33 years

2012

294

PROFIT X PRICE MACK

Financial Results MACK

MACK cash flow

Asset, Revenue and Profit Growth - MACK

MACK balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

NVO - Novo Nordisk

Frequently Asked Questions